Increasing Hemagglutination Inhibition Antibodies against Two Lineages of Type B Influenza Virus in 2017-2018 Winter Season in Beijing, China

Yao Yao  
Beijing Children's Hospital

Lingling CHEN  
CDC

Dong ZHU  
Beijing Qsinghua Changgung Hospital

Runqing LI  
Beijing Qsinghua Changgung hospital

Zhipeng ZHAO  
Beijing Qsinghua Changgung Hospital

Wenqi SONG  
Beijing Children's Hospital

Xiuying Zhao (✉️ zxy_0525@163.com)  
Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University  
https://orcid.org/0000-0001-5486-2480

Kun Qin  
CDC Public Health Library and Information Center: Centers for Disease Control and Prevention

Original article

Keywords: Type B influenza virus, Hemagglutinin inhibition (HI) antibodies, Geometric mean titer (GMT)

Posted Date: December 4th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-120270/v1

License: ☑️ Licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Influenza virus circulates every year with lower activity than that of influenza A virus in China. During 2017 to 2018 winter season, a sharp surge of influenza activity dominated by type B/Yamagata lineage virus caused unprecedented medical burden in Beijing. The research aimed to understand the underlying mechanism for this circulation and be prepared for epidemics in the future. Sera samples collected from the patients in 2016-2017 and 2017-2018 flu seasons were tested for profiling hemagglutinin inhibition (HI) antibodies against both prevailing Victoria and Yamagata lineages of type B influenza viruses. It showed that the seroprevalence against both lineages of the virus in 2017-2018 winter was higher than that in 2016-2017, while no difference of the seroprevalence was observed between the two viruses. Meanwhile, significant elevated geometric mean titer (GMT) against both lineages of influenza B viruses was found in the specimens collected during 2017-2018 flu season than that from 2016-2017, suggesting the viruses might undergo antigenic changes. These results also suggested that lower GMT against both type B variants in 2016-2017 might serve as an immunological niche for the dominating of B/Yamagata virus in China during 2017-2018 winter season. Our findings have implication that there was a significantly elevation of HI antibodies to influenza viruses B in 2017-2018, compared in 2016-2017. On the other hand, the low level of HI antibodies to both B/Y and B/V in 2016-2017 could contribute to the severe B/Y epidemic in 2017-2018 to some extent.

Introduction

Since October 2017, information from the World Health Organization (WHO) has highlighted the increasing level of influenza activity compared with previous flu seasons (WHO, 2018). It dramatically reached the peak and caused a huge medical burden in Beijing and such situation had been lasting till April, 2018 (Kochanek et al. 2018). Sharply increasing number of patients with influenza-like-Illness (ILI) suggested that the circulating virus might have evaded the herd immunity or mutated to achieve a higher transmissibility (Bedford et al. 2015). This predication soon was confirmed by the evidence from China CDC that Yamagata lineage of type B influenza virus (Flu B) was the predominant strain resulting the epidemic, although few cases were reported to be type A influenza virus (Flu A) infection including pdmH1N1/2009 and H3N2 (CDC. 2018).

Flu B virus firstly identified in 1940 was associated with consolidate hospital admissions and deaths worldwide annually (FRANCIS. 1940; Chen and Holmes. 2008). During early 1980s, it evolved into two lineages, designated as B/Yamagata (B/Y) and B/Victoria (B/V), showing distinct antigenicity and transmission pattern (Chen R et al. 2008; Kanegae et al. 1990; Vijaykrishna et al. 2015). Since then, Flu B viruses have co-circulated with Flu A virus during epidemic season and the dominant lineage has changed over years in different geographical locations (Ye et al. 2018; Yang et al. 2018). Several studies have pointed out the differences of the epidemiology between B/Y and B/V lineages, such as younger average ages of persons preferred being attacked by and higher transmissibility of B/V viruses, compared with B/Y viruses (Vijaykrishna et al. 2015; Caini et al. 2019; Yoshihara et al. 2019).

For a long time, much effort has been done on Flu A virus, whereas Flu B virus was relatively less investigated, resulting in poor lineage matches with recommended influenza vaccine strains and the control options require further improvement (Htwe et al. 2019; Noh et al. 2018). HI tests measure the presence of specific antibodies of IgG in sera that inhibit virus-mediated agglutination of erythrocytes (Rowe et al. 1999). This is a sensitive assay that is affected, in some level, by nonspecific hemagglutinin inhibitors in the sera. However, it is a particularly reliable method for influenza surveillance, providing confirmative result for suspect individuals with successive sera samples, also profile the herd immunity against upcoming influenza variant, in which case tiers ≥ 1:40 are considered protective (Skevaki et al. 2012). In the present study, serological assay against two lineages of Flu B viruses circulating in China was determined to investigate the cross-sectional HI antibodies in defined samples. Our findings provided insights on low level herd immunity to influenza B virus prior to the B/Y lineages epidemic would in some level contribute to this epidemic.

Materials And Methods

Sera samples and ethics approval

Two batches of serum samples from Beijing Tsinghua Changgung Hospital (BTCH) and Beijing Children Hospital (BCH), respectively, were used in the present study. Batch one was 190 sera samples collected during Nov, 2016 to Apr, 2017 (2016–2017) from outpatients in BTCH with the age ranging from 0.5 to 94 years old. Batch two was 283 sera samples collected from outpatients presenting acute respiratory infections (ARI) from BCH during the Dec, 2017 to Mar, 2018 (2017–2018), with the age ranging from 0.5 to 17 years old. Samples in Batch one was subdivided into 3 groups according to ages and diagnosis, group 1 from 69 adults aged from 18 to 94 years old and excluded respiratory diseases, group 2 from 75 patients aged from 0.5 to 17 years old present other than respiratory symptoms, group 3 from 46 patients aged from 0.5 to 17 years old and presenting ARI. All sera samples were remaining from routine clinical tests and were stored at -40 °C till use. The studies did not involve any health-related patient information and were approved by the Ethics Committee of both Beijing Children's Hospital and Beijing Tsinghua Changgung Hospital (Approval No. 2018-k-130 / 17120-0-01).

Representative influenza viruses for HI assay

Type B influenza viruses isolated from China during the two winter seasons were selected for HI assay on the basis of data collected by the World Health Organization (WHO) as well as our own study (Zhu et al. 2019). For Victoria lineage, B/Jiangxi_yushui/11102/2014 which was phylogenetically and antigenically close to the recommended vaccine strain B/Brisbane/60/2008, belonging to V1A sublineage, was selected as the antigen for HI. For Yamagata lineages, the representative virus B/Beijing/BTCW_71/2018, belonging to Y3 sublineage isolated in early 2018 in Beijing was used (Zhu et al. 2019). The phylogenetic relationship of the selected viruses was presented (Fig. 1). Viruses were amplified in 9-11-day-old specific pathogen free (SPF) chicken embryonated eggs at 35 °C for 2 days. The allantoic fluid were collected and cleared by low-speed centrifugation. The titer of the virus was determined by HA assay and viral antigen aliquots were stored at -80 °C till use. All experiments associated with live viruses were performed in the biosafety level 2 plus laboratory.
HI titers in 2017–2018 than in 2016–2017, either to B/Yamagata (though the HI positivity to B/Y lineage did mildly increase than B/V (66.08% vs 59.72%, against B/Y lineage and 59.72% showed HI positive against B/V lineage in the 2017–2018, with no signicant difference was observed to B/Y and B/V Flu B viruses, with the frequency at 23.14%, and no difference being found between B/Y and B/V lineage. However, there were 66.08% showed HI positive and no difference being found as cut-off limit for “positive reaction” of recently infection.

Hemagglutination inhibition (HI) assay

Serum samples were examined for the presence of antibodies against the hemagglutinin of the selected type B influenza viruses by HI assay as described previously (Bodewes et al. 2011; Wang et al. 2012). Briefly, serum samples were heat inactivated at 56 °C for 1 hour and then were absorbed by 20% (v/w) turkey red blood cell (TRBC) to reduce the non-specific binding. 2-fold serial dilutions with 1:10 starting dilution of pretreated serum samples were subsequently incubated with 8 hemagglutination units of influenza virus or phosphate-buffered saline (PBS) for 30 min at 37 °C, and subsequently, 1% TRBC was added. HI pattern were read after incubation for 30 min at 22 °C. The highest dilution of serum that still gave complete inhibition of the hemagglutination was recorded as the titer. Serum samples were considered negative when they failed completely to inhibit agglutillation of TRBC by any of the selected viruses. Serum samples collected from mice before and after immunization with each of the type B influenza viruses were used as negative and positive controls, respectively. Considering previous exposures to Flu B viruses or vaccinations in individual’s life would have interference on HI antibody profile, we took as cut-off limit for “positive reaction” of recently infection.

Statistics

Data analyses were performed using SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA). Nonparametric test was used for comparing the age difference of children and GMT of the sera samples. Correlation of HI titers against two lineages of Flu B virus was employed Spearman tests. The Pearson Chi-square test or Fisher’s exact tests were performed to evaluate HI antibodies seroprevalence to Yamagata and Victoria lineages of Flu B virus, with cut-off value as HI titers ≥ 1:80. Two-sided at the 5% level of signicance was considered statistically remarkable in all tests.

Results

HI titers against two lineages of Flu B viruses in sera from 2016–2017

The HI titers to the two lineages of Flu B viruses in sera from 2016–2017 were compared. Result indicated that the frequency with HI titers over the cut-off value in the 3 subgroups did not show difference, either to B/Y, or to B/V lineage virus (Table 1). HI titers in group 3, the sera from children present ARI did not increase as compared to the group 2, sera from children without ARI (P = 0.47 for B/Y and P = 0.78 for B/V). Hence, we put group 2 and group 3 together (n = 121) to represent HI value in children (CHI) from 2016–2017. The HI titers in CHI group were also compared to subgroup 1 of adults and no difference was found (P = 0.65 for B/Y and P = 0.49 for B/V). The results indicated a lower epidemic of Flu B in 2016–2017 winter, with the HI titers in children and adult showing no difference previous the B/Y epidemic year.

Table 1: Summary and comparing of HI titers to B/Y and B/V lineages in 2016–2017

<table>
<thead>
<tr>
<th>Sera cohorts</th>
<th>Group1 (N = 69) No. (%)</th>
<th>Group2 (N = 75) No. (%)</th>
<th>Group3 (N = 46) No. (%)</th>
<th>P value (3 groups)</th>
<th>P value (group 2 to 3)</th>
<th>P value (CHI to adults)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B/Yamagata†</td>
<td>14(20.29)</td>
<td>19(25.33)</td>
<td>9(19.57)</td>
<td>0.69</td>
<td>0.47</td>
<td>0.65</td>
</tr>
<tr>
<td>B/Victoria§</td>
<td>13(18.84)</td>
<td>18(24.00)</td>
<td>10(21.74)</td>
<td>0.76</td>
<td>0.78</td>
<td>0.49</td>
</tr>
<tr>
<td>P value</td>
<td>1.00</td>
<td>1.00</td>
<td>1.00</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

The percentages were estimated as a fraction of total cases belonging to each category. P values were estimated using χ² tests or Fisher’s exact tests (between B/Y and B/V of each group).

† CHI: summary of group 2 and group 3 to represent samples from children. Adults: samples from adult in group 1

§ B/Beijing/BTCH_71/2018 was used as antigen representative of B/Yamagata lineage virus.

Comparing HI titers against two lineages of Flu B viruses in 2016–2017 and 2017–2018

HI titer against prevailing Flu B viruses was compared using sera samples from 2016–2017 and 2017–2018. All the samples from children aged 0.5–17 years and no difference being found (P = 0.77). There were 28 sera samples in 2016–2017 CHI (n = 121) groups being found as HI positive against both lineages of Flu B viruses, with the frequency at 23.14%, and no difference being found between B/Y and B/V lineage. However, there were 66.08% showed HI positive against B/Y lineage and 59.72% showed HI positive against B/V lineage in the 2017–2018, with no significant difference was observed to B/Y and B/V lineages in this season, though the HI positivity to B/Y lineage did mildly increase than B/V (66.08% vs 59.72%, P = 0.054). It was significantly increased as the HI titers in 2017–2018 than in 2016–2017, either to B/Yamagata (P < 0.01) and B/Victoria (P < 0.01), indicating that HI antibody in children increased
simultaneously, to both B/Y and B/V viruses with the spreading of B/Y lineage (Table 2). On the other hand, a moderate correlation was found between HI titers to B/V and B/Y in 2016–2017 ($r = 0.58$) and 2017–2018 ($r = 0.49$) (Fig. 2).

<table>
<thead>
<tr>
<th>Sera cohort/Antigen</th>
<th>2016–2017 (N = 121)</th>
<th>2017–2018 (N = 283)</th>
<th>$p$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>B/Yamagata†</td>
<td>28 (23.14%)</td>
<td>187 (66.08%)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>B/Victoria‡</td>
<td>28 (23.14%)</td>
<td>169 (59.72%)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>$P$ value</td>
<td>1.00</td>
<td>0.054</td>
<td>/</td>
</tr>
</tbody>
</table>

The percentages were estimated as a fraction of total cases belonging to each category. $P$ values were estimated using $\chi^2$ tests or Fisher’s exact tests (age groups), and $p$ values of 0.05 or less are shown in bold.

†. B/Beijing/BTCH_71/2018 was used as the representative of B/Yamagata lineage virus.

‡. B/Jiangxi_Yushui/11102/2014 was used as the representative of B/Victoria lineage virus.

Figure 2. Comparison of HI titer distributions against two lineages of Flu B viruses by Spearman tests.

We can see categories of HI titer to both lineages increased significantly in 2017–2018 than in 2016–2017. Moderate correlation can be found between B/Y and B/V lineage as the HI titers in 2016–2017 (a) and 2017–2018 (b).

## Antigenic drift of Flu B viruses from 2016–2017 to the 2017–2018

Geometric mean titer (GMT) was usually used for evaluating the influenza vaccine efficacy and potency in defined population. In the study, the GMT of HI titer against both lineages of Flu B viruses in sera collected in 2017–2018 (74.16 against B/Y and 67.57 against B/V, respectively) was much higher than that collected in 2016–2017 (31.87 against B/Y and 26.44 against B/V, respectively). Significant increase in the GMT to both lineages could be seen in 2017–2018, as compared to 2016–2017. However, we did not find difference as the GMT to B/Y and B/V either in 2016–2017 ($P = 0.14$), or in 2017–2018 ($P = 0.11$). Given the same antigens used in the HI assay for sera samples from two different years, we predict that Flu B viruses might undergo antigenic drift and it is the reason for the B/Y lineage virus evades herd immunity. Collectively, these data suggested weak HI response in 2016–2017 to both Flu B viruses may contribute to the severe epidemic of Flu B in winter of 2017 (Table 3), and the antigenic drift produce a transition and higher HI titers against most recent/homologues infection.


<table>
<thead>
<tr>
<th>Sera cohorts</th>
<th>B/Yamagata† (95% CI)</th>
<th>B/Victoria‡ (95% CI)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016–2017 (N = 121)</td>
<td>31.87 (27.56–36.86)</td>
<td>26.44 (21.54–32.46)</td>
<td>0.14</td>
</tr>
<tr>
<td>2017–2018 (N = 283)</td>
<td>74.16 (66.39–82.83)</td>
<td>67.57 (60.51–75.44)</td>
<td>0.11</td>
</tr>
<tr>
<td>$P$ value</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td></td>
</tr>
</tbody>
</table>

GMT was calculated based on the HI titer. $P$ values were estimated using nonparametric tests and $p$ values of 0.05 or less are shown in bold.

†. B/Beijing/BTCH_71/2018 used as the representative of B/Yamagata lineage virus.

‡. B/Jiangxi_Yushui/11102/2014 used as the representative of B/Victoria lineage virus.

§. CI, Confidence interval.

## Discussion

The HI assay serves as a golden method for serologic diagnosis of influenza, if suitable viral antigen was employed. In the context that an abrupt spread of influenza B/Y lineage virus, we performed this HI antibody screening study using cryopreserved sera samples, aiming to evaluate the HI antibody transition after the outbreak of B/Y lineage. Setting 1:80 as cut-off value, we compared the positivity of HI titer and GMT to both B/Y and B/V lineages in 2017–2018 to previous year of 2016–2017. Result indicated that the positivity of HI titer in 2017–2018 was significantly higher than that in 2016–2017, and the GMT was
also significantly increased in 2017–2018 than the previous year. However, we did not find any difference as the HI titers to B/Y and B/V in the two consecutive years. In 2016–2017, positivity and GMT of HI titer to both B/Y and B/V were at a low level. Significantly, in 2017–2018, positivity and GMT of HI titers to B/Y and B/V increased simultaneously, though many reports indicated that B/Y was the leading reason for severe spreading of influenza during the time (Dayan. 2018). The HI antibody to B/Y lineage with percentage of 66.1% exceeds reported positivity of antigen tests to Flu B at around 10–20%, and reported positivity of RT-PCR assay to Flu B at 38% in ILI cases during 2017–2018 winter, suggesting recessive infection would be a primary reason for acquiring the HI antibodies under Flu B epidemic.

Sudden surge of Flu B/Y virus during the 2017–2018 winter may reflect changes of the viral fitness (Virk et al. 2019), as well as herd immunity against this leading strain. The prevailing B/Y variant become to dominate might reflect the vaccine effectiveness (VE) or natural situation cannot provide adequate protective immunity against this strain. In this study, low GMT of HI to both B/Y and B/V in previous epidemic year (2016–2017) add value to this assumption and reinforce the emergence of the B/Y epidemic. HI titer could not only serve as an indicator for the protective immunity after the immunization, but also hint infection/transmission status in a well-defined population (Bodewes et al. 2011). Flu B had been detected at very low incidence in ILI patients during 2018–2019 seasonal flu epidemic (unpublished data by our group), which could be attributed to previous year's development of HI antibodies to B/Y and B/V lineages.

In China, general public has gradually developed a strong "vaccine hesitancy". People including high risk individuals are reluctant or refuse to be vaccinated despite the availability of influenza vaccine due to a variety of reasons. Influenza vaccination coverage rate in China was at 1.5% of the total population between 2004 and 2014 (Yang et al. 2016). It can be postulated that establishment of herd immunity against influenza virus mainly relies on the natural infection. Low immunization coverage and lack of B/Y antigen in current trivalent influenza vaccine (TIV) in China (before 2018–2019 flu season) may provide favorable conditions for the dominance and prevalence of B/Y virus. Long-term co-circulating viruses of Flu A H1/H3 subtype accompanied by decreased HI antibody to both Flu B virus may serve as an immunological niche for the B/Y lineage virus spreading in China during the 2017–2018 winter. Our findings have implications that quadrivalent influenza vaccines (QIV) should be timely updated for better prevention against seasonal influenza epidemics.

Abbreviations

HI
Hemagglutinin inhibition
GMT
Geometric mean titer
WHO
World Health Organization
ILI
Influenza-like-illness
Flu B
Type B influenza virus
Flu A
Type A influenza virus
B/Y
B/Yamagata
B/V
B/Victoria
BTCH
Beijing Tsinghua Changgung Hospital
BCH
Beijing Children Hospital
ARI
Acute respiratory infections
SPF
Specific pathogen free
TRBC
Turkey red blood cell
PBS
Phosphate-buffered saline
CHI
HI value in children
VE
Vaccine effectiveness
TIV
Trivalent influenza vaccine
QIV
Quadrivalent influenza vaccines

Declarations

Ethics approval and consent to participate

Not applicable. This article does not contain any studies with human participants performed by any of the authors, so the consent to participate is not applicable.

Consent for publication

Not applicable.

Competing interests

The authors have no conflicts of interest to declare.

Availability of data and materials

All relevant data are within the manuscript.

Funding

This work was supported by a grant from Beijing Municipal Science & Technology Commission Program of China (grant no. Z181100001718148).

Contributions

ZHAO Xiuying and QIN Kun conceived and designed research. Yao Yao and CHEN Lingling conducted experiments. SONG Wenqi, Zhao Zhipeng and LI Runqing helped to conduct experiments. QIN Kun and CHEN Lingling analyzed data. Zhao Xiuying and QIN Kun wrote the paper. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Dr. Xiuying Zhao and Dr. Kun Qin.

References


Accessed January 28 2018

FRANCIS T (1940) A NEW TYPE OF VIRUS FROM EPIDEMIC INFLUENZA. Science 92:405–408


Figures
Figure 1

Phylogenetic tree of the HA gene of type B influenza viruses used in the study. Phylogenetic tree was constructed using the partial HA genes (370-610NT covering the most important positions distinguishing the Victoria and Yamagata lineages) from the clinic isolates and full-length HA sequences from the GenBank as well as GISAID. Strains labeled with black triangle represented as B/Victoria and B/Yamagata lineage viruses were used as antigens in the present study.

Figure 2

Comparison of HI titer distributions against two lineages of Flu B viruses by Spearman tests. We can see categories of HI titer to both lineages increased significantly in 2017-2018 than in 2016-2017. Moderate correlation can be found between B/Y and B/V lineage as the HI titers in 2016-2017 (a) and 2017-2018 (b).